



ASX & Media Release

Patrys and Garvan Institute of Medical Research Awarded Grant

Melbourne, Australia; 16 October, 2017: Patrys Limited (**ASX: PAB**), a clinical stage biotechnology company and Sydney's Garvan Institute of Medical Research (Garvan) have recently finalized the terms of a Federal Government Innovation Connections grant to support research within the PAT-DX1 program. The Garvan is one of Australian's leading biomedical research institutes.

The research will be undertaken by Dr Marina Pajic, Leader in the Personalised Cancer Therapeutics Laboratory. Since 2013, Dr Pajic has been driving research to develop novel clinically relevant tailored treatment strategies for pancreatic cancer through collaborative Australian Pancreatic Cancer Genome Initiative (APGI) studies at Garvan as part of the International Cancer Genome Consortium sequencing effort. Dr Pajic has established unique research tools for studying pancreatic cancer.

The Innovation Connections grant of \$50,000 will be used to determine the efficacy of PAT-DX1 in *in vitro* studies of pancreatic cancer cell lines, and selected well-characterised pancreatic cancer models both as a single agent and in combination with therapies commonly used in this space.

"This is the first time we have collaborated with Garvan and we are very pleased to establish a relationship with Dr Pajic and her expert team. The collaboration should provide data regarding the potential effectiveness of PAT-DX1 as a treatment for pancreatic cancer, which has the highest mortality rate of all major cancers," said Dr James Campbell, Chief Executive Officer and Managing Director of Patrys. "The Federal Government's Innovation Connections scheme plays a critical role in nurturing partnerships between Australian based companies and the research sector."

Dr Marina Pajic said, "We are enthusiastic to work with Patrys to investigate the utility of PAT-DX1 in pancreatic cancer. The Innovation Connections grant program is supporting exciting innovative technology with the potential for improving patient outcomes."

Patrys expects to be able to report on the research findings in 2018.

About Deoxymab 3E10 and PAT-DX1

Patrys has a worldwide license to develop and commercialize as anti-cancer agents a portfolio of pre-clinical novel anti-DNA antibodies and antibody fragments/variants and antibody-nanoparticle conjugates discovered at Yale University.

Deoxymab 3E10 is an autoantibody originally identified in models of lupus. Unlike normal antibodies that bind to foreign cells (eg pathogens) or aberrant cells (eg cancer cells) and trigger an immune response, autoantibodies bind to normal cells. Of particular interest with Deoxymab 3E10 is that whilst



most antibodies bind to markers on the surface of cells, Deoxymab 3E10 penetrates cells' nuclei and binds directly to DNA. Having bound to the DNA, Deoxymab 3E10 inhibits DNA repair and damages DNA. Normal cells repair DNA damage utilizing intact DNA repair processes, however Deoxymab 3E10 can kill cells that have mutations or deficiencies in DNA repair mechanisms as found in various cancer cells. As well as showing single agent therapeutic potential, Deoxymab 3E10 has been shown to significantly enhance the efficacy of both chemo- and radiotherapies. Further, 3E10 can be conjugated to nanoparticles to target delivery of chemotherapeutics to tumors.

Patrys has developed a humanized form of Deoxymab 3E10, PAT-DX1 which is significantly more effective than the original version of 3E10, and is progressing this, and a nanoparticle-conjugated form of PAT-DX1-NP towards the clinic. In a range of pre-clinical cancer models PAT-DX1 has shown significant ability to kill cancer cells in cell models, human tumor explants and xenograft models. Patrys believes that PAT-DX1 may have application across a wide range of malignancies such as gliomas, melanomas, prostate, breast, pancreatic and ovarian cancers.

About the Innovation Connections Program

The Federal Government's Innovation Connections program provides small and medium sized businesses with support to collaborate with the research sector in developing new ideas with commercial potential.

About the Garvan Institute of Medical Research

The Garvan Institute of Medical Research is one of Australia's largest medical research institutes. Garvan's main research areas are: cancer, diabetes and metabolism, genomics and epigenetics, immunology and inflammation, osteoporosis and bone biology, and neuroscience. Garvan's mission is to make significant contributions to medical science that will change the directions of science and medicine and have major impacts on human health.

-Ends-

For further information, please contact:

Patrys Limited:

James Campbell
Chief Executive Officer
P: +61 3 96703273
info@patrys.com

Media and IR:

Kyahn Williamson
Buchan Consulting
P: +61 3 9866 4722
kwilliamson@buchanwe.com.au

About Patrys Limited:

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of antibodies as therapies for a range of different cancers. Patrys has a pipeline of anti-cancer antibodies for both internal development and as partnering opportunities. More information can be found at www.patrys.com.